The Global Digital Therapeutics (DTx) Market was valued US$ 4.28 billion in 2021 and is predictable to reach US$ 16.13 billion by 2028; growing at a CAGR of 20.9% from 2021 to 2028. Evidence based therapies via software such as health apps which replaces or boost the prevailing treatment of a disease. DTx are the therapeutic intrusions indicated for a precise disease and intended to enhance the behaviour of the patient by improving the behaviour of the patient. It offers wide range of products such as mobile apps, sensors and wearable devices.
Growing adoption of smart devices such as smartphones and tablets with healthcare apps, increasing chronic cases and necessity to control the cost associated with healthcare projects for the market rise of global digital therapeutics market are expected to boost the market in the coming years. Cardiovascular disease is the prime cause for the casualties worldwide accounting for 17.3 million per year. However, approvals for the apps concerning the product and data quality, decisions making reliability, privacy of the patients are still initiation phase. However, absence of awareness for the healthcare applications and security concerns of data breach hinders the market revenue share and growth.
Geographically, countries like China, India and Middle East are expected to see increased growth for the digital therapeutics. However, several regions are still in its infancy owing to minimum solution availability, lack of awareness, lacking IT infrastructure facilities and financial and societal constraints. Estimation prediction shows 70% of the total deaths in the growing regions and globally will be reaching about 60% for chronic cases. Educating the people for the use of digital therapeutics, especially older population shows greater susceptibility to diseases as they use least digital therapeutics products with lower literacy levels.
North America holds major share owing to the presence of prominent competitors, mounting government initiatives, well-developed healthcare infrastructure, and rising prevalence of chronic health issues. Asia-Pacific is expected to garner highest growth in the digital therapeutics (DTx) market during the forecast period. Growth in adoption of smartphones, evolution in consciousness of newer technologies, and rise in consumer likings maintaining healthy lifestyles are key factors which would complement for the adoption of digital therapeutics (DTx).
Increasing high speed internet and rising cases of diseases such as diabetes, obesity, and others affecting the lifestyle will further drive the growth of the Asia-Pacific digital therapeutics (DTx) market. However, lower accuracy, frail reimbursement options, and low acceptance of devices among geriatric population are the factors that hinder the market growth.
Prominent competitors inducing the Digital Therapeutics (DTx) Market are Noom, Livongo Health, Omada Health, WellDoc, Pear Therapeutics, Proteus Digital Health, Propeller Health, Akili Interactive Labs, Better Therapeutics, Happify, Kaia Health, Mango Health, Click Therapeutics, Canary Health, Wellthy Therapeutics, Cognoa, CogniFit, Ayogo Health, Mindstrong Health, 2Morrow, and Ginger among others.
Digital Therapeutics (DTx) Market Segmentation:
By Sales Channel
- Pharmaceutical Companies
- Preventive Applications
- Lifestyle Management
- Treatment/Care-related Applications
- CNS Disorders
- Mental Health Disorder
- Other CNS Disorders
- Respiratory Disorders
- Musculoskeletal Disorders
- Cardiovascular Diseases
- Smoking Cessation
- Medication Adherence
- Gastrointestinal Disorders
- Substance Use & Addiction Management
- Rehabilitation & Patient Care
- Other Treatment/Care-related Applications
- North America
- Rest of North America
- Rest of Europe (RoE)
- Asia Pacific
- Rest of Asia Pacific
- Rest of the World (RoW)
- South & Central America
- Middle East